Telitacicept for autoimmune nephropathy

被引：21
作者：
Cai, Jingjing [1 ]
Gao, Dan [1 ,2 ,3 ,4 ]
Liu, Dongwei [1 ,2 ,3 ,4 ]
Liu, Zhangsuo [1 ,2 ,3 ,4 ]
机构：
[1] Zhengzhou Univ, Dept Integrated Tradit & Western Nephrol, Affiliated Hosp 1, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Res Inst Nephrol, Zhengzhou, Peoples R China
[3] Henan Prov Res Ctr Kidney Dis, Zhengzhou, Peoples R China
[4] Key Lab Precis Diag & Treatment Chron Kidney Dis H, Zhengzhou, Peoples R China
来源：
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
基金：
中国国家自然科学基金;
关键词：
B-cell activating factor BAFF; a proliferation-inducing ligand APRIL; telitacicept; lupus nephritis; IgA nephropathy; B-LYMPHOCYTE STIMULATOR; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CHINESE PATIENTS; IGA NEPHROPATHY; PLASMA-CELLS; BAFF; DISEASE; APRIL; EXPRESSION; EFFICACY;
D O I：
10.3389/fimmu.2023.1169084
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
B cells and the humoral immunity are important players in the pathogenesis of autoimmune diseases. BAFF (also known as BLYS) and a proliferation-inducing ligand APRIL are required for the maintenance of the B-cell pool and humoral immunity. BAFF and APRIL can promote B-cell differentiation, maturation, and plasma cell antibody secretion. BAFF/APRIL overexpression has been identified in several autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, IgA nephropathy, etc. Telitacicept, a novel fully human TACI-Fc fusion protein that binds both BAFF and APRIL, was approved in China in March 2021 for the treatment of systemic lupus erythematosus at a recommended dose of 160 mg/w subcutaneously and is in clinical trials for the treatment of multiple indications in other autoimmune diseases. In this review, we explored telitacicept's mechanism of action and clinical data. In addition, the immune features of autoimmune nephropathy were discussed, emphasizing lupus nephritis, IgA nephropathy, and membranous nephropathy.
引用
收藏
页数：9
相关论文
共 65 条
  • [1] BAFF mediates survival of peripheral immature B lymphocytes
    Batten, M
    Groom, J
    Cachero, TG
    Qian, F
    Schneider, P
    Tschopp, J
    Browning, JL
    Mackay, F
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (10) : 1453 - 1465
  • [2] M-Type Phospholipase A(sub 2) Receptor as Target Antigen in Idiopathic Membranous Nephropathy.
    Beck, Laurence H., Jr.
    Bonegio, Ramon G. B.
    Lambeau, Gerard
    Beck, David M.
    Powell, David W.
    Cummins, Timothy D.
    Klein, Jon B.
    Salant, David J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (01) : 11 - 21
  • [3] B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time
    Becker-Merok, A.
    Nikolaisen, C.
    Nossent, H. C.
    [J]. LUPUS, 2006, 15 (09) : 570 - 576
  • [4] APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells
    Belnoue, Elodie
    Pihlgren, Maria
    McGaha, Tracy L.
    Tougne, Chantal
    Rochat, Anne-Francoise
    Bossen, Claudia
    Schneider, Pascal
    Huard, Bertrand
    Lambert, Paul-Henri
    Siegrist, Claire-Anne
    [J]. BLOOD, 2008, 111 (05) : 2755 - 2764
  • [5] Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis
    Bracewell, C.
    Isaacs, J. D.
    Emery, P.
    Ng, W. F.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (07) : 909 - 919
  • [6] The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus
    Cancro, Michael P.
    D'Cruz, David P.
    Khamashta, Munther A.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (05) : 1066 - 1073
  • [7] Cao X., 2018, MED IMMUNOLOGY, V9th Ed, P78
  • [8] Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis
    Chen, Xia
    Zhao, Qian
    Hou, Yong
    Jiang, Ji
    Zhong, Wen
    Wang, Wenxiang
    Yao, Xuejing
    Li, Lin
    Fang, Jianmin
    Zhang, Fengchun
    Hu, Pei
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (01) : 41 - 52
  • [9] Pharmacokinetics, Pharmacodynamics, and Tolerability of Single Ascending Doses of RCT-18 in Chinese Patients with Rheumatoid Arthritis
    Chen, Xia
    Hou, Yong
    Jiang, Ji
    Zhao, Qian
    Zhong, Wen
    Wang, Wenxiang
    Yao, Xuejing
    Li, Lin
    Fang, Jianmin
    Zhang, Fengchun
    Hu, Pei
    [J]. CLINICAL PHARMACOKINETICS, 2014, 53 (11) : 1033 - 1044
  • [10] Telitacicept Following Plasma Exchange in the Treatment of Subjects With Recurrent NMOSD: Study Protocol for a Single-Center, Single-Arm, Open-Label Study
    Ding, Jie
    Cai, Yu
    Deng, Ye
    Jiang, Xianguo
    Gao, Meichun
    Lin, Yan
    Zhao, Nan
    Wang, Ze
    Yu, Haojun
    Lv, Wenwen
    Zhang, Ying
    Hao, Yong
    Guan, Yangtai
    [J]. FRONTIERS IN NEUROLOGY, 2021, 12
1234567